US Sues Idaho Over Abortion Law

The United States sued Idaho on Tuesday over a state law that it says imposes a "near-absolute ban" on abortion and also sought to block the Western state from prosecuting or disciplining doctors, according to a court filing.

The lawsuit, filed in U.S. District Court for Idaho, seeks a preliminary and permanent injunction against the state prohibiting enforcement of the law and asked the court to rule that the state law violates federal statutes.

The lawsuit also alleges the state law interferes with the United States’ pre-existing agreements with hospitals under Medicare, referring to the federal health care program for seniors.

"Today, the Justice Department's message is clear ... if a patient comes into the emergency room with a medical emergency jeopardizing the patient's life or health, the hospital must provide the treatment necessary to stabilize that patient," U.S. Attorney General Merrick Garland said at a news conference in Washington announcing the filing.

"This includes abortion, when that is the necessary treatment," Garland added.

Tuesday's lawsuit marks the Justice Department's first legal battle over reproductive rights since the Supreme Court in June overturned the landmark 1973 Roe v. Wade ruling that recognized women's constitutional right to abortion.

Idaho in March became the first state to enact a six-week abortion ban modeled on a Texas law that empowers private citizens to sue abortion providers. The law bans abortion before many women know they are pregnant.

Source: Voice of America

America’s Biggest Warehouse Running Out of Room; It’s About to Get Worse

America's largest warehouse market is full as major U.S. retailers warn of slowing sales of the clothing, electronics, furniture and other goods that have packed the distribution centers east of Los Angeles.

The merchandise keeps flooding in from across the Pacific, and for one of the busiest U.S. warehouse complexes, things are about to get worse.

Experts have warned the U.S. supply chain would get hit by the "bullwhip effect" if companies panic-ordered goods to keep shelves full and got caught out by a downturn in demand while shipments were still arriving from Asia.

In the largest U.S. warehouse and distribution market — stretching east from Los Angeles to the area known as the "Inland Empire" — that moment appears to have arrived.

"We're feeling the sting of the bullwhip," said Alan Amling, a supply-chain professor at the University of Tennessee.

The sprawl of Inland Empire warehouses centered in Riverside and San Bernardino counties grew quickly in recent years to handle surging demand and goods imported from Asia.

That booming area, visible from space, anchors an industrial corridor encompassing 1.6 billion square feet of storage space that extends from the busiest U.S. seaport in Los Angeles to near the Arizona and Nevada borders. That much storage space is nearly 44 times larger than New York City's Central Park and 160 times bigger than Tesla Inc's TSLA.O new Gigafactory in Texas.

But a consumer spending pullback now threatens to swamp warehouses here and around the country with more goods than they can handle — worsening supply — chain snarls that have stoked inflation. Retailers left holding unwanted goods are faced with the choice of paying more money to store them or denting profits by selling them at discount.

Inland Empire warehouse vacancies are among the lowest in the nation, running at a record 0.6% versus the national average of 3.1%, according to real estate services firm Cushman & Wakefield.

The market is poised to get even tighter as shoppers at Walmart WMT.N, Best Buy BBY.N and other retailers retreat from early COVID-era spending binges.

Binge to backlog

While U.S. consumer spending remains above pre-pandemic levels, retailers and suppliers are raising alarms about backlogs in categories that have fallen out of fashion as consumers catch up on travel and struggle with the highest inflation in 40 years.

Last week, Walmart said surging food and fuel prices left its lower-income customers with less cash to spend on goods, and Best Buy said shoppers were curbing spending on discretionary products like computers and televisions. Those cautionary signals followed Target Corp's TGT.N alert that it was saddled with too many TVs, kitchen appliances, furniture and clothes.

Suppliers — ranging from barbecue grill maker Weber Inc WEBR.N to Helen of Troy Ltd HELE.O, a consumer brands conglomerate that includes OXO kitchen tools — also have warned of slowing demand and an urgent need to clear inventories.

While the U.S. economy was downshifting, goods kept pouring in at near-record levels.

Imports to U.S. container ports that process retail goods from China and other countries jumped more than 26% in the first half of 2022 from pre-pandemic levels, according to Descartes Datamyne. Christmas shipments and the reopening of major Chinese factory hubs could goose volumes further.

Meanwhile, cargo keeps flooding in to the busiest U.S. seaport complex at Los Angeles/Long Beach. During the first half of this year, dockworkers there handled about 550,000 more 40-foot containers than before the pandemic started, according to port data.

Christmas toys and winter holiday decor landed on those docks in July, along with some patio furniture for Walmart and stretch pants, jeans and shoes for Target, said Steve Ferreira, CEO of Ocean Audit, which scrutinizes marine shipping invoices.

Retailers ordered most of those goods months ago and many are destined for the Inland Empire's already jam-packed warehouses.

"It's a domino effect. Now the inventory is going to really build up," said Scott Weiss, a vice president at Performance Team, a Maersk MAERSKb.CO company with 22 warehouses in greater Los Angeles.

Demand for space in the Inland Empire is so intense that when 100,000 to 200,000 square feet of space frees up, it "gets gobbled up in a second," said Weiss.

Sears and parking lots

Investors have almost 40 million square feet under construction in the Inland Empire — including Amazon.com Inc's AMZN.O biggest-ever warehouse — and at least 38% is spoken for, said Dain Fedora, vice president of research for Southern California at Newmark, a commercial real estate advisory firm.

While Amazon's 4.1 million square-foot facility rises on former dairy land in the city of Ontario, the online retailer has been shelving construction plans in other parts of the country.

Amazon is the biggest warehouse tenant in the Inland Empire and the nation. Its decision to scale back on building, coupled with rising interest rates and the slowing economy, is sidelining other would-be Inland Empire warehouse builders, area real estate brokers and economists told Reuters.

Meanwhile, the scramble for space continues.

Trucking company yards and spare lots around the region have already been converted to makeshift container storage, so entrepreneurs are marketing vacant stores as last-resort warehouses in waiting.

Brad Wright is CEO of Chunker, which bills itself as an AirBNB for warehouses, and works with everyone from state officials to the owners of vacated big-box stores to find new places to stash goods.

During a recent tour at the former Sears anchor store in San Bernardino's Inland Center mall, Wright and a potential tenant strolled past collapsed ceiling tiles, sagging wall panels and idled escalators while working out how forklifts would navigate the abandoned space. Wright sees the empty stores as one answer to easing the log jams.

"There's a lot of them sitting around, and they're in good locations," he said.

Source: Voice of America

Mindset Change; a password to sustainable development!

Richard, 2022[i] notes that mindset influences how one thinks, feels and behaves in a given situation. Mindsets can be individual or they can be embedded in protocols of organizations, for example, the military may have its own mindset just as the church may have its own mindset. Mindsets are conventional wisdoms and help create standard practices that support people and organizations to function efficiently. Mindsets are also known to stimulate both productivity and unproductive resistance.

As part of the webinar series to discuss the 5 sense-making papers on philanthropy, Uganda National NGO Forum in collaboration with Centre for Basic Research held a webinar on 28th July 2022 to discuss Sense-Making Policy Paper 4 – Philanthropy and Mindset Change. Moderated by Ms. Isabella Akiteng (Imara Women’s Centre, FOWODE), this webinar provided a forum to discuss the issues around mindsets that inform philanthropy and giving.

Mr. Richard Ssewakiryanga, the lead researcher and presenter of the sense-making papers, highlighted two forms of mindset i.e. the growth mindset and the fixed mindset. In the fixed mindset, people/institutions believe that their qualities are carved in stone, while in the growth mindset is based on the belief that your basic qualities are things you can cultivate through your efforts, strategies and help from others. Richard called for a shift in philanthropy mindsets from predominant fixed mindsets and orthodoxies to a growth mindset that builds opportunities for transformation.

The Technical Advisor – Parish Development Model, Ministry of Local Government, Mr. Julius Kapwepwe, who was the lead discussant decried the issue of identity crisis that has for long existed in Africa despite being a rich continent with vast resources which can be leveraged by our communities. He highlighted Karamoja region which is rich with minerals and wildlife but currently presented by the media and other stakeholders as an impoverished community. While referencing the Government’s Parish Development Model (PDM), he called for a mindset shift in order to empower communities to appreciate the enormous potential that is within their reach and explore it through community philanthropy.

While giving her closing remarks, the chief guest – Ms. Angella Nakafeero re-echoed and added her voice to the participants’ to celebrate the vast resources that exist in our communities and thus called for favorable development approaches that will spur innovation and creativity in communities to enable philanthropy to thrive. She also called for strengthened documentation of giving practices and their impact as part of motivating other people/communities to embrace philanthropy.

From the conversations during this webinar, there was unanimous appreciation by participants that Africa, and Uganda in particular, has a lot of resources that can easily spur community development. The only password/puzzle that needs to be unlocked is the mindset shift from appreciating that development comes from within and can only be propelled by the outside.

Source: Uganda National Ngo Forum

AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

AOP Health commence la recherche d’un traitement pour la leucémie

AOP Health a signé un accord avec Leukos Biotech pour la poursuite du développement d’une substance chimique récemment découverte. Avec cet accord, AOP Health élargit encore davantage le domaine de la recherche sur l’hémato-oncologie et propose des options de traitement supplémentaires à certains patients atteints de leucémie sur le long terme.

VIENNE, Autriche, 01 août 2022 (GLOBE NEWSWIRE) — AOP Health Group (AOP Health) est un pionnier européen des thérapies intégrées pour les maladies rares et les soins intensifs basé à Vienne, en Autriche. La société se concentre sur la recherche, le développement et la vente mondiale de solutions de traitement innovantes et se spécialise dans les thérapies pour les maladies rares et les soins intensifs. Début juillet, AOP Health a signé un accord avec Leukos Biotech, une société dérivée fondée par l’institut de recherche sur la leucémie Josep Carreras, basé à Barcelone. L’accord signé par AOP Health couvre l’option de développement de la substance chimique récemment découverte dans le cadre de toute indication traitable, non limitée aux maladies oncologiques ou rares.

L’accord établit la base de nouveaux domaines thérapeutiques

Dans un premier temps, AOP Health se concentrera sur le développement d’options de traitement pour la leucémie myéloïde aiguë (LMA) et le syndrome myélodysplasique (SMD). Les deux sont des types particuliers de leucémie qui commencent souvent dans la moelle osseuse. Agnes Kohl, directrice commerciale d’AOP Orphan Pharmaceuticals GmbH, membre du groupe AOP Health, explique : « Sur la base de données positives, notre plan est d’étendre le développement d’autres indications orphelines même en dehors de la LMA et du SMD à un stade ultérieur. Grâce à cet accord, nous pourrons peut-être élargir le portefeuille de nos domaines thérapeutiques en offrant encore plus d’options de traitement aux patients. »

Développement en coopération avec Leukos

Comme AOP Health se concentre sur les cancers hémato-oncologiques rares et possède de nombreuses années d’expérience dans le développement et la commercialisation de traitements hémato-oncologiques, la société pilotera le développement ultérieur de la substance en coopération avec Leukos sur la base d’un nouveau mode d’action. Cela pourrait potentiellement devenir une étape importante dans le traitement de nombreux cancers du sang et autres patients atteints de cancer. Luis Ruiz-Avila, PDG de Leukos Biotech : « Nous nous concentrons sur le développement de nouveaux traitements pour une grande variété de tumeurs. Nous sommes nés pour transformer l’excellente science de l’Institut de recherche sur la leucémie Josep Carreras en produits précieux pour les patients atteints de cancer dans le besoin, et cet accord est une étape très importante dans cette direction. Nous sommes convaincus qu’AOP Health est le bon partenaire pour transformer ce nouveau mécanisme d’action prometteur en une réalité clinique au profit des patients présentant une grande variété de besoins médicaux non satisfaits. »

À propos d’AOP Health

Le groupe AOP Health comprend plusieurs sociétés, dont AOP Orphan Pharmaceuticals GmbH, dont le siège se trouve à Vienne, en Autriche (« AOP Health »). Le groupe AOP Health est le pionnier européen des thérapies intégrées pour les maladies rares et les soins critiques. Au cours des 25 dernières années, le groupe est devenu un fournisseur établi de solutions de thérapie intégrées opérant depuis son siège social à Vienne, ses filiales et ses bureaux de représentation à travers l’Europe et le Moyen-Orient, ainsi que par l’intermédiaire de partenaires dans le monde entier. Ce développement a été rendu possible par un niveau d’investissement continu élevé dans la recherche et le développement, d’une part, et par une orientation très cohérente et pragmatique vis-à-vis des besoins de toutes ses parties prenantes, d’autre part, en particulier les patients et leurs familles, ainsi que les professionnels de la santé qui les prennent en charge.

À propos de Leukos

Leukos Biotech, SL (Leukos) est une société dérivée de l’Institut de recherche sur la leucémie Josep Carreras, créée à Barcelone en 2015. La société développe de nouveaux traitements et outils de diagnostic pour une large variété de tumeurs ciblant le récepteur de la sérotonine HTR1B, dont le potentiel antitumoral a été décrit pour la première fois et breveté par le Dr Ruth Risueño, fondateur de Leukos dans son laboratoire à l’Institut de recherche Josep Carreras. Le principal soutien financier de Leukos provient d’investisseurs privés et institutionnels. Les principaux actionnaires sont Inveready, CDTI Innvierte et la Fondation Josep Carreras. Outre le soutien des investisseurs, Leukos a reçu des subventions et des prêts non dilutifs du gouvernement catalan, du gouvernement espagnol et de l’Union européenne dans le cadre de divers programmes.

À propos de la Fondation Josep Carreras

La Fondation Josep Carreras Leukaemia a été créée en 1988 dans le but de contribuer à la recherche d’un remède définitif pour cette maladie. Ses efforts se concentrent sur quatre domaines fondamentaux : l’administration du Registre espagnol de donneurs de moelle osseuse (REDMO), la recherche scientifique menée par l’Institut de recherche sur la leucémie Josep Carreras, l’orientation des patients via un canal de consultation des patients en ligne et des appartements d’accueil pour les patients qui ont besoin de subir un traitement et doivent passer beaucoup de temps loin de chez eux.

À propos de l’Institut de recherche sur la leucémie Josep Carreras

L’Institut de recherche sur la leucémie Josep Carreras, centre public appartenant au réseau CERCA de la Generalitat de Catalunya, a été créé en 2010 dans le but de promouvoir la recherche biomédicale et la médecine personnalisée dans le domaine de la leucémie et d’autres maladies onco-hématologiques. Il s’agit du premier centre de recherche européen exclusivement dédié à la leucémie et aux hémopathies malignes, et l’un des rares au monde. Les Instituts Josep Carreras disposent de trois campus scientifiques coordonnés mais indépendants : le Campus clinique de l’Hôpital de l’Université de Barcelone, le Campus de l’Institut catalan d’oncologie/allemands Trias i Pujol et le Campus de Sant Pau – Autonomous University of Barcelona (UAB).

À propos d’Inveready

Inveready est un gestionnaire d’actifs alternatifs de premier plan en Espagne ; il investit dans le capital-risque en phase de démarrage, le capital-risque de croissance, la dette à risque, les actions stratégiques dans des sociétés cotées, les infrastructures et le capital-investissement privé. Il fournit des solutions de financement aux entreprises tout au long de leur cycle de vie. Fondée en 2008, Inveready compte sur 200 sociétés actives et plus d’un milliard d’euros d’actifs sous gestion. Inveready investit dans des entreprises du secteur des sciences de la vie depuis 2008. Les investissements notables dans ce secteur sont Atrys Health (cotée sur le marché espagnol), EDESA Biotech (cotée au Nasdaq), AVX Pharma (vendue à Aerie Biotech) et PaloBiofarma (accord de licence avec Novartis). Le siège social de la société se situe à San Sebastian et elle possède d’autres bureaux à Barcelone et Madrid. La société a été reconnue à plusieurs reprises par l’ASCRI et Preqin pour le rendement de ses fonds et de ses transactions (Pour plus d’informations, veuillez consulter le site www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Besoins. Science. Confiance.

AOP Orphan Pharmaceuticals GmbH
Membre du groupe AOP Health

Leopold-Ungar-Platz 2, 1190 Vienne, Autriche
aop-health.com

Des photographies accompagnant ce communiqué sont disponibles aux adresses :

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease  

WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.

“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Uganda To Use Tatu City For Benchmarking

The Uganda Parliament will use Tatu City as a benchmark for the successful implementation of Special Economic Zones (SEZ).

This follows a successful visit by members of the parliamentary Budget Committee to the 5,000-acre new city.

In a press statement by the Tatu City Monday, the Uganda delegation of nine MPs who also visited the government-managed SEZ, Konza Technopolis, were making a tour to understand and also learn on operational manuals for special economic zones.

The Ugandan delegation, led by the Committee’s Deputy Chairman, Ignatius Wamakuyu stated that their country was in the process of operationalizing laws and policies to guide the development of SEZs in recognition of the important role they play in job creation and GDP growth.

“We came here to see and understand the policies, legal framework and other operational manuals for Special Economic Zones and the more reason we have met with different players in Kenya,” Wamakuyu said.

He noted that after learning and touring, they will thereafter generate a report that can be discussed in their National Assembly, together with recommendations to the Executive to initiate such developments.

The Ugandan government has implemented a hybrid model with a few industrial parks, but is now looking to expand these into full-fledged SEZs.

“Uganda is endowed with many raw materials and minerals, which will be exploited, once such facilities (SEZs) are established in the country,” said Wamakuyu, adding that the neighbouring country has also a large population of young people, who are more than 51 percent and who will benefit greatly from such facilities.

He explained that the budget committee’s job is to do appropriations, and look at them when the government brings proposals to fund such private entities.

“We have disagreements about why the government is putting money in such facilities. However, we have seen how the government can step in to invest in infrastructure for the benefit of the country,” Wamakuyu said.

Tatu City’s Director of Industrial Operations Tito Oduk said they have several businesses at the facility, which have operations in Uganda or trade with them, which shows that the two countries are both interconnected.

“We had fruitful discussions with the visiting members of parliament, about making laws that accelerate business within the EAC, with common tariffs for both private and public SEZs,” said Oduk.

Tatu City, Kenya’s first fully operationalized SEZ, currently hosts more than a dozen SEZ enterprises, with dozens of additional companies in the process of establishing operations.

According to Oduk, over 5,000 jobs have so far been created at Tatu City, with an additional 10,000 expected in the next 14 months as more businesses establish themselves.

To date, Tatu City has welcomed more than 70 companies, including Dormans, Copia, Cooper K-Brands, Maxxam, Twiga Foods, Freight Forwarders Solutions, Friendship Group, Davis & Shirtliff and KWAL.

Source: Kenya News Agency

Two Dead After UN Troops Open Fire at DRC Uganda Border Post

The U.N. peacekeeping mission in the Democratic Republic of Congo has arrested U.N. peacekeeping troops suspected of having opened fire on a Ugandan border post, killing at least two people and injuring 15 others. It’s the latest violent incident involving the U.N.’s mission to the DRC, which has been facing violent protests.

In a statement, the U.N. mission at the Congo-Uganda border at Kasindi said the soldiers from a MONUSCO intervention brigade force were returning from leave when they opened fire on the border post.

The Sunday incident took place in DRC as the troops crossed from Uganda back into Congo.

The special representative of the secretary of general of the U.N. in Congo Bintou Keita described the incident as unspeakable and irresponsible behavior and said the soldiers opened fire for “unexplained reasons.” Keita said the U.N. had contacted the soldiers’ countries of origin so that legal proceedings can be initiated against the perpetrators.

DRC authorities said among those injured during the incident were two policemen who were working at the barrier and eight civilians.

Congolese government spokesman Patrick Muyaya said the peacekeepers involved in the incident will be suspended from Congo pending the outcome of plans to withdraw the entire MONUSCO force from DRC.

Nearly 20 people have been killed in eastern Congo since protests began on July 25.

The protestors who stormed the U.N. base in Goma accuse the mission of failing to achieve peace since they began operations in Congo 20 years ago.

The mission in Goma Monday paid tribute to four of its members who were killed during the anti-MONUSCO protest in North Kivu. In a tweet MONUSCO said the ceremony took place in the presence of the leadership of the mission and the head of the U.N.’s department of peace operations.

Source: Voice of America

Lawlessness in Eastern Congo Takes Aim at Journalists

Journalists have gone into hiding in fear for their lives in eastern Democratic Republic of Congo following increased attacks by rebel group M23, which controls the Bunagana area near the Rwandan and Ugandan borders.

One community radio station went off the air in mid-June, and two of its journalists later were detained for two days, ending with several hours of torture. They were told they’d be killed if they worked with the government army.

M23 accuses reporters and civilians of collaborating with government soldiers and informing them about the group’s positions and hideouts, journalists say.

In an interview with the Committee to Protect Journalists (CPJ) last week, a spokesman for M23 denied attacks on journalists.

The Voice of Mikeno (RACOM), a community radio station in Bunagana, was vandalized after M23 rebels took control of the key border town June 13.

That day, a transmitter, solar panels, computers and other equipment were taken, allegedly by M23 rebels. RACOM, a VOA affiliate, has been off the air since then, and all its 20-plus staff members are in hiding.

One RACOM journalist spoke to VOA’s Swahili Service after requesting anonymity to protect his safety.

Identified here as “Oscar,” he said he was detained by M23 members while interviewing residents in Nyakabande refugee camp in Kisoro, Uganda. He said he later learned from colleagues that another RACOM journalist, Henry Hererimana Serushago, was detained from the same camp on the same day.

The two journalists separately were taken back to Bunagana town. Oscar said the rebels tied up and whipped him for several hours before releasing him July 5, adding that he was told “to go and never continue working with the army.”

Serushago also was tied up, beaten, kicked and whipped – and threatened with death if he talked about the mistreatment, he told CPJ in an interview. He also was released July 5.

Like Oscar, Serushago is in hiding. Journalists close to him told the VOA Swahili Service that he lives in fear and does not want his whereabouts known.

Eastern Congo, which borders Rwanda, lives under daily threat from scores of armed groups that jostle for a piece of the region’s mineral riches. The world mines it for gold, diamonds and material for electric cars, laptops and mobile phones.

M23, one of the most notorious rebel groups, surged into action late last year. Congo has accused Rwanda of supporting the M23, which Rwanda denies.

On June 20, East African leaders meeting in the Kenyan capital, Nairobi, responded to the threat of war by instructing a new regional force to deploy in eastern Congo and by ordering an immediate cease-fire.

That has not stopped violence in the area.

At least 12 civilians were killed July 26 at protests against the United Nations peacekeeping mission offices in the city of Goma and town of Butembo. Protesters claim the mission has failed to protect civilians from militia violence.

One U.N. soldier and two U.N. police were also killed.

On July 13, “M23 rebels were crossing into Uganda from Democratic Republic of Congo and recruiting members,” Haji Shafiq Sekandi, Kisoro resident district commissioner in Uganda, was reported by local media as saying.

One VOA stringer, a veteran of covering the DRC conflict, said he also has received threats from callers identifying themselves as members of M23.

In one typical call, he was told, “You have hatred toward us. Soon you will be captured together with [government] soldiers.”

The stringer said he talked to M23 commanders directly within and outside DRC to explain to them the nature of his job, but the threatening messages still come.

Tuver Wundi coordinates the media rights group Journalists in Danger and denounced the attacks in eastern DRC.

“A journalist is not in any way involved in conflict. He only informs people what is happening during war,” Wundi told the VOA Swahili Service. “We don’t understand why they should attack journalists.”

“Many journalists in areas controlled by M23 have been threatened and are in hiding,” he said. “Community radio journalists are in hiding. They no longer want to work in Bunagana. They are not even comfortable answering phone calls. They prefer switching off their phones.”

Speaking to CPJ last week, the M23 official David Mugabe said the July 5 attack on Serushago “did not happen” and that M23 did not raid RACOM’s office. He suggested other armed groups or people with personal “vendettas” were to blame.

The M23 rebel group is now targeting civilians, Human Rights Watch (HRW) said.

In a report last week, HRW blamed M23 for the deaths of 29 civilians, including two teenagers, since mid-June. Some of those killed were shot as they attempted to flee. Others were executed at close range.

“Since the M23 took control of several towns and villages in North Kivu in June, they’ve committed the same kind of horrific abuses against civilians that we’ve documented in the past,” HRW said.

The U.N. peacekeeping mission in DRC – which includes civilians, police and military personnel – has around 12,400 troops and costs more than $1 billion per year. It has been gradually withdrawing from the area for several years.

The protests continue.

On July 31, two people were killed and 15 injured after U.N. forces opened fire during an incident on the Uganda border, Agence France-Presse reported.

A total of five U.N. peacekeepers – three Moroccans and two Indians – died last week, with three of the fatalities linked to violent protests in the town of Butembo.

Source: Voice of America

Uganda Monitors DRC Border After Deadly Shooting

Ugandan police are deploying a standby force to the border with the Democratic Republic of Congo (DRC) after U.N. peacekeeping troops opened fire on a border post, killing two people and wounding 15, including an 8-year-old Ugandan girl.

Uganda says it has deployed a team to monitor ongoing tensions in the eastern DRC resulting from a deadly shooting involving MONUSCO soldiers.

The incident that has been described in a statement by the U.N. Special Representative Bintou Keita as unspeakable and irresponsible happened in the town of Kasindi in the DRC’S Beni territory close to Uganda.

The statement said that during the incident, soldiers from the Intervention Brigade of the MONUSCO force from Tanzania, returning from leave, opened fire at the border post for unexplained reasons and forced their way through.

Fred Enanga, the Uganda Police spokesperson, described the incident.

“So, one of the bullets strayed and hit an eight-year-old juvenile called Bira Jackline,” he said. “She’s getting treatment at Bwera hospital. The stray bullet hit her shoulder and it was retrieved. So, she’s out of danger.”

In his statement, Bintou said the perpetrators of the shooting were identified and arrested pending the conclusions of the investigation, which has already started in collaboration with Congolese authorities.

Bintou added that contact had also been established with Tanzania so that legal proceedings can be initiated urgently with the participation of victims and witnesses.

MONUSCO, the peacekeeping mission in the DRC, was in 2010 given the mandate to carry out offensive operations. In another statement, U.N. Chief Antonio Guterres said he was saddened and outraged by the incident and demanded accountability.

With ongoing tension between DRC locals and MONUSCO, Enanga said authorities are monitoring the situation.

“We’ve been closely monitoring what happened from the other side of Bunagana and DRC,” he said. “We don’t want the violence there to affect our borderline. We have a standby team monitoring.”

Trade between DRC and Uganda slowed down since March due to the resumption of fighting between DRC government forces and M23 rebels who took over the town of Bunagana. Uganda has since March registered 41,164 asylum seekers comprising 21,235 households.

Source: Voice of America